Skip to Content
  • The Landscape of Kinase Inhibitors

    I’ve been meaning to link to this article, which is the best overview I know of for kinase inhibitors. The authors (a large multicenter team led out of Mu… Read More
  • The Drug Project Landscape

    Here’s a new paper in Nature Reviews Drug Discovery that’s going to the trouble of matching specific disease indications with specific mechanisms in… Read More
  • Drug Development Costs Revisited

    A recent paper on drug development costs did not impress me. But if possible, it impressed Matthew Herper at Forbes even less. That’s the one where the au… Read More
  • Whole Classes of Things

    We all know about target-based drug discovery. Enough biology has been learned that we think that Protein X is operating at a crucial stage in the development o… Read More
  • Alnylam Breaks Through

    As a pioneer in RNAi therapeutics, Alnylam has really had some ups and downs over the years (some of them chronicled on this blog). Today would be one of the &# Read More
  • It Costs More Than This

    Here’s another paper on the cost to develop a new drug, a topic about which, I’m convinced, debate will never end. This one is designed as a respons… Read More
  • AMPK: Time To Think Hard

    AMP-activated protein kinase, now that’s an enzyme for you. It sits at the center of a cell’s metabolic switchboard, and if you’re talking abo… Read More
Page 1 of 5412345...102030...Last »